Zacks Research Has Bearish Estimate for CORT Q1 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Investment analysts at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for Corcept Therapeutics in a research note issued on Wednesday, March 19th. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings per share of $0.17 for the quarter, down from their prior forecast of $0.29. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics' Q4 2025 earnings at $0.63 EPS and Q1 2026 earnings at $0.45 EPS.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.37 by ($0.11). The business had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%.

CORT has been the topic of several other reports. HC Wainwright restated a "buy" rating and set a $115.00 price objective on shares of Corcept Therapeutics in a report on Thursday, February 27th. Canaccord Genuity Group raised their price target on Corcept Therapeutics from $78.00 to $130.00 and gave the company a "buy" rating in a research note on Thursday, January 30th. Piper Sandler upped their price objective on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Finally, StockNews.com cut shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $99.75.

Remove Ads

Corcept Therapeutics Trading Down 0.8 %

Shares of NASDAQ:CORT traded down $0.43 during trading on Monday, reaching $56.68. 431,493 shares of the company were exchanged, compared to its average volume of 968,580. The business's fifty day simple moving average is $61.86 and its 200-day simple moving average is $54.31. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. Corcept Therapeutics has a 12-month low of $20.84 and a 12-month high of $75.00. The firm has a market capitalization of $5.98 billion, a PE ratio of 44.98 and a beta of 0.61.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Synergy Asset Management LLC increased its position in shares of Corcept Therapeutics by 131.3% in the 4th quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company's stock valued at $22,369,000 after acquiring an additional 262,503 shares during the period. Van ECK Associates Corp purchased a new stake in Corcept Therapeutics during the 4th quarter valued at about $4,483,000. Victory Capital Management Inc. raised its stake in shares of Corcept Therapeutics by 49.2% in the third quarter. Victory Capital Management Inc. now owns 41,823 shares of the biotechnology company's stock worth $1,936,000 after purchasing an additional 13,787 shares during the last quarter. State Street Corp raised its stake in shares of Corcept Therapeutics by 0.6% in the third quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company's stock worth $162,871,000 after purchasing an additional 19,893 shares during the last quarter. Finally, Burney Co. lifted its holdings in shares of Corcept Therapeutics by 9.1% during the fourth quarter. Burney Co. now owns 473,821 shares of the biotechnology company's stock worth $23,876,000 after purchasing an additional 39,657 shares during the period. Hedge funds and other institutional investors own 93.61% of the company's stock.

Insider Buying and Selling

In other news, insider Sean Maduck sold 20,000 shares of the business's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the sale, the insider now owns 85,318 shares in the company, valued at approximately $4,299,174.02. The trade was a 18.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph K. Belanoff sold 2,924 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $60.91, for a total transaction of $178,100.84. Following the transaction, the chief executive officer now owns 3,019,411 shares in the company, valued at approximately $183,912,324.01. This trade represents a 0.10 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,022 shares of company stock worth $2,703,257 in the last ninety days. 20.50% of the stock is owned by insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.